Development of a Prospective Monocentric Clinico-Biological Database for Bronchial Cancer
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 750
- 试验地点
- 1
- 主要终点
- Proportion of patients who consent to participate in the study
研究概览
简要总结
A Clinical and Biological Database will provide to the scientific community a collection of blood and tissues with clinical data to improve knowledge about cancer and help to develope new cancer treatments. This database is specific to bronchial cancer.
详细描述
Lung cancer is the leading cause of cancer-related mortality and the third most commonly diagnosed cancer. In France in 2018, it accounted for 46,363 new cases and 33,117 deaths. The overall 5-year survival rate across all stages and sexes is 20%.
Diagnosis is most often made at the metastatic stage, which significantly worsens the prognosis. Since 2020, the standard treatment for such cases has been the administration of intravenous chemo-immunotherapy, in the absence of a molecular alteration that allows for access to an oral targeted therapy. Immunotherapy and targeted therapies have considerably improved the prognosis for some patients, but the vast majority experience therapeutic resistance, either early or delayed.
The prognostic and predictive mechanisms of treatment response are poorly understood and vary greatly between histological and molecular subtypes. It is therefore crucial to gain a better understanding of these mechanisms in order to ultimately identify new therapeutic avenues to improve patient outcomes.
The first step in this process is to establish a tissue and blood biobank from patients with bronchial carcinoma (both small-cell and non-small-cell) treated at our center.
The Clinical Biological DataBase (BCB) is a tool:
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patient aged over 18 years,
- •Histologically or cytologically confirmed bronchial cancer,
- •Treatment-naïve patient for the current cancer,
- •Patient who has provided informed, written, and explicit consent,
- •Patient affiliated with the French national health insurance system.
排除标准
- •Patient with a WHO performance status ≥ 3,
- •Pregnant and/or breastfeeding woman,
- •Patient with a history of other cancers within the 5 years preceding inclusion,
- •Patient for whom regular follow-up is considered impossible due to psychological, familial, social, or geographic reasons,
- •Patient under legal protection (guardianship, curatorship, or judicial protection).
研究组 & 干预措施
Bronchial cancer
Additionnal samples from routine care of different natures (blood, tumor tissue ans healthy tissue) and standardized clinical data will be entered into a database.
干预措施: Blood and tissue sampling (Biological)
结局指标
主要结局
Proportion of patients who consent to participate in the study
时间窗: through study completion : an average of 1 year
the proportion of patients who consent to participate in the study among the screened patients
次要结局
未报告次要终点